N/A Completed N=53,969

Medical Need of OAC Reversal

Atrial Fibrillation

Source: ClinicalTrials.gov NCT03254147 ↗

Enrolled (actual)

53,969

Serious AEs

—

Results posted

Mar 2019

Primary outcomePrimary: The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma. — 14; 35; 84 Number of Patients

Summary

This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF

Outcome Measures

Outcome	Result	p-value
PRIMARY The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma.	14; 35; 84	—
SECONDARY The Number of Patients With Cardiac Tamponade and Pericardiocentesis.	1	—

Eligibility Criteria

Inclusion Criteria

->18 year old non-valvular atrial fibrillation (NVAF) patients

Prescribed dabigatran, rivaroxaban, apixaban, edoxaban or warfarin
Patients with confirmed date of initiation of OACs
Patients with a minimum of 6 months of enrolment data prior to index date
Has an index date between 14th of March 2011 to 30 June, 2016

Exclusion Criteria

Patients receiving two or more oral anti-coagulants at the same time at index date
Patients with prescriptions of index treatment in the 6 months prior to index date
Patients without enrolment period of at least six month in the database

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03254147). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.